logo
Highmark Blue Cross Blue Shield expands virtual care to include pelvic health, joint pain

Highmark Blue Cross Blue Shield expands virtual care to include pelvic health, joint pain

Highmark is continuing its efforts to increase access to health care by offering new ways for members to receive care virtually.
The most recent addition is Virtual Pelvic Health, Bloom by Sword, a program designed to address pelvic health dysfunction, such as bladder issues, chronic pelvic pain and other symptoms. Highmark introduced it in July 2024 and has since seen more than 10,000 members enroll.
'Virtual care is an important part of Highmark's overall Living Health strategy,' said Mari Vandenburgh, vice president of health programs and solutions.
'Highmark believes it's our responsibility to make it easier for members to access the care they need when they need it,' Vandenburgh said. 'As an integrated health system, we are in a unique position to break down barriers to care by offering ease of access and use through our virtual solutions that can complement the care members are receiving in person with their provider of choice.'
A new approach
The Virtual Pelvic Health program is Highmark's second with Sword Health Inc., a New York-based AI health company that specializes in digital health solutions. It is part of Highmark's benefits and available to eligible health plan members at no additional out-of- pocket cost. Participants simply enroll in the program through the My Highmark app or member portal.
Once enrolled, participants are matched with a pelvic health clinician and receive an FDA-listed insertable device and access to a mobile app. A personalized set of pelvic floor exercises are recommended, and the sensor and app work together to monitor the force, endurance and accuracy of the pelvic floor muscles during the exercises.
'That real-time feedback helps participants maximize their results,' Vandenburgh said.
'The Virtual Pelvic Health program provides convenient, on-demand access to pelvic floor care that is focused on both strengthening and relaxation,' she said. 'The combination of the sensor and the feedback that a user receives in the app really helps to monitor progress in their program. The app also provides educational resources to individuals that help to support behavior change and habit formation in the population of individuals that could benefit from pelvic floor support.'
Participants have reported significant improvements in their quality of life, including a reduction in symptoms they previously experienced. Additionally, the program has helped alleviate the stigma often associated with pelvic floor conditions, improving mental health.
Virtual joint health
The Virtual Pelvic Health program follows Highmark's introduction of Virtual Joint Health, Thrive by Sword to self-funded plans in 2022. In that program, a licensed physical therapist assigns a series of exercises for people looking to alleviate musculoskeletal pain based on their specific goals.
Participants then receive a tablet they can use at home as they complete the exercises. The tablet is equipped with advanced motion sensing technology to provide real-time feedback and ensure people use proper form. It also shares data with their physical care specialist to monitor progress and, if necessary, adjust their recommended exercise plan to better accommodate their needs.
'It really enables members to address their joint health needs at the time that's most convenient for them,' Vandenburgh said. 'They can do the exercises in the comfort of their own home, and it reduces the barriers of time and access to care if there are delays in getting appointments.'
In 2024, the insurer expanded it to fully insured plans. So far, more than 36,000 Highmark members have enrolled in the program.
The feedback has been positive, Vandenburgh said, with 88% of participants describing it as easy to use and 72% completing the program.
Health outcomes also have been strong, with 69% of participants reporting a significant improvement in their joint pain and 35% reduction in the intent to pursue surgery to address their pain.
'Another positive outcome that users report is that 26% say they saw an improvement in their work and productivity impairment,' she said. 'We're also monitoring the behavioral health impacts of joint health and increasing screenings for depression and anxiety.'
Expanded reach
Highmark's virtual care offerings include a virtual triage tool, virtual primary care, a virtual urgent care clinic and virtual specialty care clinics for behavioral health, women's health and dermatology, as well as a digital diabetes management solution.
Offering on-demand, virtual care helps people get the care they need to improve their health while lowering costs, Vandenburgh said. The Virtual Joint Health program, for example, has reduced costs by $112 per member per month in comparison to a control group. That savings can then be reinvested back into delivering a remarkable health experience, so it's easier for members to engage and manage their health.
'Virtual Joint Health and Virtual Pelvic Health deliver a win-win combination by boosting employer productivity and lowering cost, while simultaneously enabling employees convenient access to care and improved quality of life,' she said. 'We see continued growth in engagement and enrollment in our digital solutions and programs year over year.'
To learn more visit https://www.highmark.com/employer.
Lauren Lawley Head is a freelance writer.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)
LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)

Associated Press

time17 minutes ago

  • Associated Press

LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Lineage, Inc. (NASDAQ: LINE) and certain of the Company's senior executives and directors for potential violations of the federal securities laws. If you invested in Lineage, you are encouraged to obtain additional information by visiting: Investors have until September 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to Lineage's registration statement for its initial public offering held on or about July 25, 2024. The case is pending in the U.S. District Court for the Eastern District of Michigan and is captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al., No. 2:25-cv-12383. Why Was Lineage Sued Under the Federal Securities Laws? Lineage is a cold storage focused real estate investment trust ('REIT'). Through its Global Warehousing Segment, Lineage owns and operates hundreds of temperature-controlled storage facilities used by companies to store food and other perishable products. As alleged, Lineage's IPO documents touted its 'consistent cold chain demand,' which purportedly provided Lineage 'with strong cash flows even during periods of broader economic stress.' The IPO documents also represented that the lingering effects of the COVID-19 pandemic had 'accelerated trends that . . . have the potential to be growth engines for the industry in coming years.' In truth, Lineage was allegedly in the midst of a sustained downturn, as its customers destocked excess inventory built up during the COVID-19 pandemic, and also shifted to leaner inventories on a go-forward basis and as more cold-storage supply came on line. Events Following the IPO On February 26, 2025, Lineage announced its fiscal Q4 2024 financial results, revealing that customers had been 'unwinding' previously 'overbuil[t]' levels of inventory, returning to a 'more normal seasonal pattern' that was expected to 'continue moving forward.' Lineage conducted its IPO at $78 per share. Since the IPO, the price of Lineage stock has fallen dramatically, to lows near $40 per share—approximately half the IPO price. Click here for more information: What Can You Do? If you invested in Lineage you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)
BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)

Associated Press

time17 minutes ago

  • Associated Press

BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE: BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: Why is BellRing Being Investigated? BellRing Brands operates in the convenient nutrition category. The Company's primary brands include Premier Protein and Dymatize, which offer ready-to-drink ('RTD') protein shakes and powders. During the relevant period, the Company stated that Premier Protein 'hit an all-time high in household penetration' and that 'demand remains strong.' The Company also stated that its growth was 'strong in all channels,' driven by 'distribution expansion, accelerating velocities and incremental promotional activity.' In truth, the Company's sales growth during the relevant period may have been driven by temporary trade inventory loading at several key retailers, not sustainable end-consumer demand. The Stock Declines as the Truth Is Revealed On May 5, 2025, after market hours, BellRing revealed that starting in Q2 2023, 'several key retailers lowered their weeks of supply on hand,' which would create a headwind to Q3 2025 growth. The Company also announced it was expanding promotions to boost sales and 'offset [] third quarter reductions in retailer trade inventory levels.' On this news, the price of BellRing stock fell $13.96 per share, or more than 18%, from $77.34 per share on May 5, 2025, to $63.38 per share on May 6, 2025. Then, on August 4, 2025, after market hours, BellRing announced disappointing quarterly consumption of Premier Protein RTD Shakes, which had been expected to outpace shipments by a wider margin given previously announced retailer destocking, but instead came 'more in line' with shipments. On this news, the price of BellRing Brands stock fell $17.46 per share, or nearly 33%, from $53.64 per share on August 4, 2025, to $36.18 per share on August 5, 2025. Click here for more information: What Can You Do? If you invested in BellRing you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 12, 2025
Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 12, 2025

Associated Press

time17 minutes ago

  • Associated Press

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 12, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) and reminds investors of the September 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times. On May 14, 2025, Biohaven issued a press release 'announc[ing] that the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the PDUFA date for the troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA.' The press release further stated that "[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84 per share, or 19.53%, to close at $15.82 per share on May 15, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Biohaven's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Biohaven class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store